A vírushepatitisek megelozése és antivirális kezelése mint a hepatocellularis carcinoma (HCC) prevenciója

Translated title of the contribution: Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

As hepatitis B and C virus (HBV, HCV) play a privotal role in the development of hepatocellular carcinoma (HCC), the prophylaxis and treatment of these infections may mean also the prevention of HCC. The primary prevention of HCC is the vaccination against HBV as well as the screening of blood donors for HBV and HCV markers. The means of secondary HCC prevention are as follows: antiviral therapy of HBV and HCV-related hepatitis and cirrhosis, screening (.,surveillance") of cirrhotic patients for HCC using alfa-foetoprotein and ultrasound, and adjuvant antiviral treatment of HCC patients following curative tumor resection/ablation. It may be anticipated that the world-wide spread of HBV vaccination, the more effective optimalized individual treatment and novel antivirals for the treatment of viral hepatitis lead to the decrease of the incidence of HCC in the not far future.

Original languageHungarian
Pages (from-to)19-26
Number of pages8
JournalOrvosi Hetilap
Volume150
Issue number1
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Chronic Hepatitis
Hepatocellular Carcinoma
Antiviral Agents
Therapeutics
Hepatitis
Vaccination
alpha-Fetoproteins
Primary Prevention
Blood Donors
Hepatitis B virus
Hepacivirus
Fibrosis
Incidence
Infection
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A vírushepatitisek megelozése és antivirális kezelése mint a hepatocellularis carcinoma (HCC) prevenciója. / Pár, A.

In: Orvosi Hetilap, Vol. 150, No. 1, 01.01.2009, p. 19-26.

Research output: Contribution to journalArticle

@article{f3394eebeac746efbb033bbf9838c53c,
title = "A v{\'i}rushepatitisek megeloz{\'e}se {\'e}s antivir{\'a}lis kezel{\'e}se mint a hepatocellularis carcinoma (HCC) prevenci{\'o}ja",
abstract = "As hepatitis B and C virus (HBV, HCV) play a privotal role in the development of hepatocellular carcinoma (HCC), the prophylaxis and treatment of these infections may mean also the prevention of HCC. The primary prevention of HCC is the vaccination against HBV as well as the screening of blood donors for HBV and HCV markers. The means of secondary HCC prevention are as follows: antiviral therapy of HBV and HCV-related hepatitis and cirrhosis, screening (.,surveillance{"}) of cirrhotic patients for HCC using alfa-foetoprotein and ultrasound, and adjuvant antiviral treatment of HCC patients following curative tumor resection/ablation. It may be anticipated that the world-wide spread of HBV vaccination, the more effective optimalized individual treatment and novel antivirals for the treatment of viral hepatitis lead to the decrease of the incidence of HCC in the not far future.",
keywords = "Antiviral therapy, Hepatitis B virus, Hepatitis C virus, Hepatocellular carcinoma, Prevention, Screening",
author = "A. P{\'a}r",
year = "2009",
month = "1",
day = "1",
doi = "10.1556/OH.2009.28529",
language = "Hungarian",
volume = "150",
pages = "19--26",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A vírushepatitisek megelozése és antivirális kezelése mint a hepatocellularis carcinoma (HCC) prevenciója

AU - Pár, A.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - As hepatitis B and C virus (HBV, HCV) play a privotal role in the development of hepatocellular carcinoma (HCC), the prophylaxis and treatment of these infections may mean also the prevention of HCC. The primary prevention of HCC is the vaccination against HBV as well as the screening of blood donors for HBV and HCV markers. The means of secondary HCC prevention are as follows: antiviral therapy of HBV and HCV-related hepatitis and cirrhosis, screening (.,surveillance") of cirrhotic patients for HCC using alfa-foetoprotein and ultrasound, and adjuvant antiviral treatment of HCC patients following curative tumor resection/ablation. It may be anticipated that the world-wide spread of HBV vaccination, the more effective optimalized individual treatment and novel antivirals for the treatment of viral hepatitis lead to the decrease of the incidence of HCC in the not far future.

AB - As hepatitis B and C virus (HBV, HCV) play a privotal role in the development of hepatocellular carcinoma (HCC), the prophylaxis and treatment of these infections may mean also the prevention of HCC. The primary prevention of HCC is the vaccination against HBV as well as the screening of blood donors for HBV and HCV markers. The means of secondary HCC prevention are as follows: antiviral therapy of HBV and HCV-related hepatitis and cirrhosis, screening (.,surveillance") of cirrhotic patients for HCC using alfa-foetoprotein and ultrasound, and adjuvant antiviral treatment of HCC patients following curative tumor resection/ablation. It may be anticipated that the world-wide spread of HBV vaccination, the more effective optimalized individual treatment and novel antivirals for the treatment of viral hepatitis lead to the decrease of the incidence of HCC in the not far future.

KW - Antiviral therapy

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Prevention

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=60749113982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749113982&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28529

DO - 10.1556/OH.2009.28529

M3 - Article

VL - 150

SP - 19

EP - 26

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 1

ER -